Optimizing the upstream portion of the gene therapy production workflow sets the stage for successful manufacturing by maximizing viral vector titers. Without the benefit of a proven template, however, process development teams must evaluate all aspects of viral vector production including:
To minimize variability and risk across these process inputs, gene therapy manufacturers can collaborate with an experienced technology partner with expertise in all aspects of viral vector production as well as related products and services.
We offer a broad portfolio of raw materials and chemical components suitable for cell culture media formulations and upstream applications used in biopharmaceutical production.
See how the Sf9 rhabdovirus-free cell line was developed and how we’ve developed a companion chemically-defined insect cell media for protein and viral expression.
The Sf-RVN® Platform is a two-part system comprising a proven Sf-9 cell line devoid of Sf-rhabdovirus (the Sf-RVN® cell line) and a chemically defined medium engineered for the cell line, the EX-CELL® CD Insect Cell Medium.
Our products and services for AAV, Lentivirus and other viral vectors provide solutions to your most challenging pain points around process development, speed, manufacturing and regulatory guidelines.
The production of AAV viral vectors for gene therapy comes with unique upstream challenges. Learn how our HEK platform can solve these challenges.
Scaling up viral vector production using adherent cell culture systems is challenging. Learn how suspension cell culture systems benefit large-scale bioprocessing.
A step-by-step overview of suspension-based, transient transfection bioreactor process development and scaleup of lentivirus production.
To address scalability challenges of AAV manufacturing, we developed an HEK293 suspension cell line that can be used across many serotypes. Get the data in this article.
Interview transcript with GTRI and their findings of using the Sf-RVN® Platform.
Frozen cells from a working or master cell bank are thawed and expanded to increase their numbers in preparation for subsequent processing steps.
Cell culture media are optimized with the appropriate nutrients, supplements, and pH for cell growth and virus production.
Cells are grown in a bioreactor or other controlled environment under specific conditions to maximize virus production.
In AAV production, host cells are lysed by chemical or mechanical means so that the viruses can be released into the media.
Unwanted whole cell and plasmid DNA is digested using a nuclease enzyme.
To continue reading please sign in or create an account.Don't Have An Account?